NS Pharma Announces FDA Clearance to InitiatePhase II Study forNS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy

PARAMUS, NJ: April 14, 2023,–NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA)has agreed to the planned Phase II study of NS-089/NCNP-02 for Duchenne muscular dystrophy. NS-089/NCNP-02 is an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

“Progress has been made in the treatment of Duchenne, but patients and families need new and more treatment options,”saidVamshiRao, MD, Ann&RobertH.LurieChildren’sHospitalofChicago.“There are currently no available antisense treatments that target Duchenne patients amenable to exon 44 skipping therapy, which is why I am excited about this program and the potential advance of effective treatments for Duchenne muscular dystrophy.”

READ THE FULL PRESS RELEASE: